No association between polymorphism in the vascular endothelial growth factor gene at position-460 and sporadic prostate cancer in the Turkish population

Molecular Biology Reports

Volumn 35, Issue 1, 2008, Pages 17-22

  Onen, Ilke H ^a   Konac, Ece ^a   Eroglu, Muzaffer ^b   Guneri, Cagri ^a   Biri, Hasan ^a   Ekmekci, Abdullah ^a  

^a GAZI UNIVERSITY   (Turkey)

^b ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Genotyping; Prostate cancer; Single nucleotide polymorphism; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER STAGING; DNA POLYMORPHISM; DNA SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BASE PAIRING; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TURKEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38349183079     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-006-9046-2     Document Type: Article

References (43)

1. Jackson MW, Bentel JM, Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157(6):2323-2328
2. Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 65:550-563
3. Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8):1493-1495
4. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676
5. Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40(1):35-39
6. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP (1999) Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100(5):547-552
7. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232-1235
8. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37(6):443-448
9. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51(5):1635-1639
10. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62(12):3369-3372
11. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC (2003) Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 62(2):374-377
12. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468-471
13. Morohashi K, Takada T, Omori K, Suzuki E, Gejyo F (2003) Vascular endothelial growth factor gene polymorphisms in Japanese patients with sarcoidosis. Chest 123(5):1520-1526
14. Han SW, Kim GW, Seo JS, Kim SJ, Sa KH, Park JY, Lee J, Kim SY, Goronzy JJ, Weyand CM, Kang YM (2004) VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology 43(9):1173-1177
15. Papazoglou D, Galazios G, Koukourakis MI, Kontomanolis EN, Maltezos E (2004) Association of-634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. Acta Obstet Gynecol Scand 83(5):461-465
16. Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, Maltezos E (2004) Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 10(5):321-324
17. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P (2004) Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53(3):861-864
18. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ (2005) Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 41(5):497-502
19. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L (2006) Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35(1-2):21-28
20. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D (1999) Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 80(5):699-703
21. Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnaley D, Ardern-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, Labrie F, Easton D, Narod SA, Tonin PN, Foulkes WD (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis 3(4):241-247
22. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL (2004) Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 25(4):447-451
23. Bott SR, Arya M, Shergill IS, Williamson M (2005) Molecular changes in prostatic cancer. Surg Oncol 14(2):91-104
24. Cancel-Tassin G, Cussenot O (2005) Prostate cancer genetics. Minerva Urol Nefrol 57(4):289-300
25. Hsieh YY, Chang CC, Tsai FJ, Yeh LS, Lin CC, Peng CT (2004) T allele for VEGF gene-460 polymorphism at the 5′-untranslated region: association with a higher susceptibility to endometriosis. J Reprod Med 49(6):468-472
26. Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY (2005) Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod 20(10):2904-2908
27. Summers AM, Coupes BM, Brennan MF, Ralph SA, Short CD, Brenchley PE (2005) VEGF-460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant 20(11):2427-2432
28. Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE (2006) Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 126(2):453-459
29. Borre M, Offersen BV, Nerstrom B, Overgaard J (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78(7):940-944
30. Lissbrant IF, Lissbrant E, Damber JE, Bergh A (2001) Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35(6):437-542
31. Nicholson B, Theodorescu D (2004) Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91(1):125-150
32. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY (2003) Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 33(10):883-890
33. Soulitzis N, Karyotis I, Delakas D, Spandidos DA (2006) Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 29(2):305-314
34. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP (1997) American joint committee cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia, pp 219-224
35. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23(3):273-279
36. Liu Y, Cox SR, Morita T, Kourembanas S (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 77(3):638-643
37. Ravindranath N, Wion D, Brachet P, Djakiew D (2001) Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22(3):432-443
38. Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, Son JW, Kim CH, Lee WK, Kam S, Park RW, Park TI, Kang YM, Kim IS, Jung TH, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 14(3):571-575
39. Papadakis ED, Soulitzis N, Spandidos DA (2002) Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87(9):1013-1018
40. Lee WC (2003) Searching for disease-susceptibility loci by testing for Hardy-Weinberg disequilibrium in a gene bank of affected individuals. Am J Epidemiol 158(5):397-400
41. Sham P (1998) Statistics in Human Genetics. Wiley and Sons, Inc., New York
42. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5(2):123-127
43. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE (1999) Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81(8):1269-1273